Clinic
Jefferson County Public Hospital District No 2
Jefferson County Public Hospital District No 2 was paid $37.38M by Medicaid between Jan 2018 and Dec 2024, across 235 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoJEFFERSON COUNTY PUBLIC HOSPITAL DISTRICT NO 2
PORT TOWNSEND, WA 98368
PORT TOWNSEND, WA 98368
33aNPI1356492953assigned 01/12/2007
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$37.38M
24GClaims482,174
24DCodes billed235
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Washington
Rank by total paid#2 of 31
Median peer was paid$338K
This provider vs. median110×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,452 | $4.87M | |
| 2019 | 69,394 | $5.24M | |
| 2020 | 60,356 | $4.39M | |
| 2021 | 78,729 | $6.02M | |
| 2022 | 73,201 | $6.51M | |
| 2023 | 74,413 | $5.51M | |
| 2024incomplete | 61,629 | $4.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 26,921 | 23,436 | $6.13M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 13,778 | 11,245 | $5.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 5,235 | 3,953 | $3.14M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.4% | 2,401 | 1,999 | $2.39M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 20,794 | 8,169 | $1.41M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 4,572 | 3,248 | $806K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 5,245 | 4,809 | $761K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.9% | 11,867 | 5,199 | $692K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 5,348 | 3,861 | $685K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 6,378 | 4,731 | $682K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 6,191 | 4,311 | $594K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.5% | 11,757 | 5,023 | $568K |
223 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 1,891 | $535K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 10,559 | $513K |
| 80053 | Comprehensive metabolic panel | 1.3% | 22,038 | $482K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.3% | 5,497 | $468K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 6,151 | $441K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 445 | $412K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,397 | $326K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,417 | $326K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,838 | $315K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,151 | $312K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,320 | $294K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15,184 | $290K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,946 | $288K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,089 | $286K |
| 80050 | General health panel | <1% | 3,814 | $284K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,187 | $283K |
| 76830 | Ultrasound, transvaginal | <1% | 1,302 | $267K |
| 96376 | <1% | 2,296 | $252K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,335 | $240K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,484 | $220K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,341 | $196K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,314 | $187K |
| 80061 | Lipid panel | <1% | 5,420 | $180K |
| 97161 | <1% | 1,974 | $165K | |
| 73130 | <1% | 1,575 | $161K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 6,531 | $158K |
| 73630 | <1% | 1,383 | $157K | |
| 73564 | <1% | 1,225 | $151K | |
| 97162 | <1% | 1,684 | $150K | |
| 73610 | <1% | 1,242 | $144K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,640 | $143K |
| 82728 | <1% | 2,514 | $143K | |
| 73030 | <1% | 1,194 | $133K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,266 | $132K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,283 | $131K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 920 | $124K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 954 | $120K |
| 84484 | <1% | 4,253 | $120K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,178 | $115K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,713 | $111K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 357 | $111K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,288 | $108K |
| 73110 | <1% | 933 | $107K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,737 | $104K |
| 83690 | <1% | 4,049 | $96K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 836 | $89K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,258 | $88K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,757 | $84K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,317 | $79K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,958 | $79K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,934 | $78K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 697 | $75K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,047 | $74K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,008 | $70K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,633 | $70K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,633 | $70K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,903 | $69K |
| 84439 | <1% | 2,718 | $61K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 241 | $60K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,677 | $57K |
| 83605 | <1% | 1,988 | $57K | |
| 85027 | <1% | 3,722 | $57K | |
| 86140 | <1% | 3,957 | $57K | |
| 81001 | <1% | 4,147 | $53K | |
| 73502 | <1% | 719 | $52K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 792 | $51K |
| 87088 | <1% | 2,653 | $49K | |
| 83880 | <1% | 1,427 | $49K | |
| 86803 | <1% | 2,028 | $49K | |
| 87077 | <1% | 2,079 | $47K | |
| 82607 | <1% | 1,272 | $45K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,744 | $44K |
| 87070 | <1% | 1,542 | $44K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,349 | $44K |
| 87186 | <1% | 1,974 | $44K | |
| 85379 | <1% | 1,242 | $43K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,903 | $41K |
| 87081 | <1% | 1,257 | $40K | |
| 85610 | <1% | 4,696 | $40K | |
| 87040 | <1% | 1,324 | $39K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 132 | $39K |
| 80306 | <1% | 1,805 | $38K | |
| 81025 | <1% | 1,794 | $37K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,147 | $37K |
| 85652 | <1% | 3,265 | $36K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 684 | $34K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,658 | $33K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 568 | $32K |
| 73562 | <1% | 341 | $32K | |
| 81003 | <1% | 3,459 | $31K | |
| 84703 | <1% | 1,078 | $30K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 639 | $30K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,523 | $27K |
| 94664 | <1% | 252 | $27K | |
| 83735 | <1% | 2,171 | $27K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 530 | $26K |
| 83550 | <1% | 1,587 | $26K | |
| 82077 | <1% | 536 | $25K | |
| 97602 | <1% | 462 | $25K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 875 | $25K |
| 84145 | <1% | 1,249 | $21K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 835 | $21K |
| 84153 | <1% | 548 | $21K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,453 | $21K |
| 83540 | <1% | 1,610 | $21K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 436 | $21K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 36 | $20K |
| 99201 | <1% | 1,282 | $19K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 319 | $19K |
| 0011A | <1% | 942 | $18K | |
| 76642 | <1% | 163 | $18K | |
| 82570 | <1% | 1,272 | $18K | |
| 86850 | <1% | 678 | $17K | |
| 87340 | <1% | 694 | $17K | |
| 0012A | <1% | 841 | $17K | |
| 59025 | Fetal non-stress test | <1% | 73 | $16K |
| 20610 | <1% | 258 | $15K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 254 | $15K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,641 | $15K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 646 | $15K |
| 84403 | <1% | 515 | $15K | |
| 84481 | <1% | 586 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 895 | $14K |
| 87205 | <1% | 1,078 | $13K | |
| 76801 | <1% | 73 | $13K | |
| 86900 | <1% | 700 | $13K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 16 | $12K |
| 81015 | <1% | 1,589 | $11K | |
| 84702 | <1% | 221 | $11K | |
| 72100 | <1% | 96 | $11K | |
| 86901 | <1% | 659 | $10K | |
| 80143 | <1% | 194 | $10K | |
| 86592 | <1% | 841 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 451 | $9K |
| 82962 | <1% | 975 | $9K | |
| 80179 | <1% | 168 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 16 | $8K |
| 81002 | <1% | 666 | $8K | |
| 82043 | <1% | 533 | $8K | |
| 76536 | <1% | 42 | $7K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 561 | $7K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $7K |
| 94060 | <1% | 36 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 25 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $6K |
| 97597 | <1% | 59 | $6K | |
| 86038 | <1% | 222 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 77 | $5K |
| 97035 | <1% | 272 | $5K | |
| 0002A | <1% | 324 | $5K | |
| 87507 | <1% | 12 | $5K | |
| 71250 | <1% | 18 | $5K | |
| 0001A | <1% | 325 | $5K | |
| 97130 | <1% | 69 | $5K | |
| 77066 | Tomosynthesis, mammo | <1% | 27 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 219 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 175 | $4K |
| 82805 | <1% | 71 | $4K | |
| 97165 | <1% | 41 | $4K | |
| 94729 | <1% | 36 | $3K | |
| 94726 | <1% | 36 | $3K | |
| 82150 | <1% | 138 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 308 | $3K |
| 97163 | <1% | 25 | $3K | |
| J3490 | Unclassified drugs | <1% | 77 | $3K |
| 82670 | <1% | 66 | $3K | |
| 84550 | <1% | 223 | $2K | |
| 73140 | <1% | 25 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $2K |
| 97129 | <1% | 75 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 50 | $2K |
| 73590 | <1% | 13 | $2K | |
| 82375 | <1% | 71 | $2K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 59 | $2K |
| 86787 | <1% | 37 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 112 | $1K |
| 90715 | <1% | 68 | $1K | |
| 97116 | <1% | 42 | $1K | |
| 96367 | <1% | 14 | $1K | |
| 83001 | <1% | 24 | $970.01 | |
| 99223 | Prolong inpt eval add15 m | <1% | 12 | $945.24 |
| 82274 | <1% | 24 | $933.94 | |
| 88342 | <1% | 12 | $920.34 | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 21 | $862.54 |
| 83050 | <1% | 71 | $818.45 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 137 | $767.16 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 53 | $692.43 |
| 87653 | <1% | 12 | $691.71 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 19 | $628.08 |
| 84402 | <1% | 26 | $607.09 | |
| 84100 | <1% | 66 | $591.33 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 37 | $532.51 |
| 86704 | <1% | 28 | $521.37 | |
| 85730 | <1% | 41 | $471.03 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 144 | $462.48 |
| 82550 | <1% | 48 | $453.41 | |
| 86308 | <1% | 25 | $439.43 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 38 | $395.17 |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 13 | $382.08 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 25 | $371.43 |
| 0031A | <1% | 16 | $334.02 | |
| 86706 | <1% | 16 | $302.42 | |
| 80305 | <1% | 13 | $298.35 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 15 | $278.10 |
| 86431 | <1% | 16 | $253.71 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 21 | $232.55 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 20 | $223.26 |
| 83615 | <1% | 18 | $219.65 | |
| 17000 | <1% | 27 | $186.69 | |
| 86430 | <1% | 12 | $186.58 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 13 | $177.37 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $154.83 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 93 | $143.69 |
| A9270 | Non-covered item or service | <1% | 4,420 | $88.93 |
| 82565 | <1% | 15 | $88.88 | |
| 91300 | <1% | 454 | $79.21 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 233 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 177 | $0.00 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 0% | 282 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 412 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 29 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 91301 | 0% | 1,648 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGLENN, MIKE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Jefferson County Public Hospital District No 2 | Port Townsend, WA | $16.39M |
| Jefferson County Public Hospital District No 2 | Port Townsend, WA | $2.68M |
| Jefferson County Public Hospital District No 2 | Port Townsend, WA | $1.63M |
| Jefferson County Public Hospital District No 2 | Port Townsend, WA | $1.57M |
| Jefferson County Public Hospital District No 2 | Port Ludlow, WA | $1.14M |
| Jefferson County Public Hospital District No 2 | Quilcene, WA | $554K |
| Jefferson County Public Hospital District No 2 | Port Townsend, WA | $956.01 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.